PLX R&D to Revenue
Protalix Biotherapeutics Inc · R&D to Revenue
PLX R&D to Revenue
Latest reported21.87%period ending
PLX Quarterly R&D/Revenue (0.00% → 21.87%)
Latest values, visible window
High-resolution chart · PNG
PLX r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 21.8687% | |
| 16.077% | |
| 61.7737% | |
| 25.0238% | |
| 38.268% | |
| 34.3617% | |
| 22.6369% | |
| 16.6936% | |
| 21.9757% | |
| 77.0277% | |
| 29.5823% | |
| 35.4664% | |
| 12.7584% | |
| 60.9825% | |
| 65.1851% | |
| 52.0764% | |
| 86.5875% | |
| 54.5042% | |
| 89.3789% | |
| 60.4115% | |
| 119.6359% | |
| 62.9152% | |
| 56.1836% | |
| 71.2512% | |
| 83.7604% | |
| 47.7686% | |
| 54.0289% | |
| 70.1853% | |
| 108.7858% | |
| 112.0605% | |
| 36.8976% | |
| 81.6457% | |
| 149.6693% | |
| 141.5111% | |
| 364.115% | |
| 84.8924% | |
| 138.8172% | |
| 160.2285% | |
| 274.2912% | |
| 108.2655% | |
| 442.0011% | |
| 887.3343% | |
| -68.7628% | |
| 89.9761% | |
| 484.3563% | |
| 399.6454% | |
| 326.3006% | |
| 164.6884% | |
| 184.7357% | |
| 82.1753% | |
| 659.3583% | |
| 167.8178% | |
| 210.7702% | |
| 134.1482% | |
| 16,435.4167% | |
| 118.0519% | |
| 35.0582% | |
| 183.5837% | |
| 319.0093% | |
| 699.47% | |
| 957.9843% | |
| 137.85% | |
| 812.8401% | |
| 111.3693% | |
| 878.7029% | |
| 643.9965% | |
| 2,198.7113% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 2,515.3333% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |